Lisata Therapeutics (NASDAQ:LSTA) Cut to “Hold” at Brookline Capital Management

Brookline Capital Management cut shares of Lisata Therapeutics (NASDAQ:LSTA) from a buy rating to a hold rating in a research note released on Wednesday morning, MarketBeat Ratings reports. Brookline Capital Management also issued estimates for Lisata Therapeutics’ FY2025 earnings at ($2.46) EPS.

Several other analysts also recently commented on the stock. Zacks Research downgraded shares of Lisata Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, November 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Lisata Therapeutics in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Lisata Therapeutics currently has an average rating of “Hold” and an average target price of $23.50.

Lisata Therapeutics Trading Up 1.2%

Shares of LSTA stock opened at $4.11 on Wednesday. The firm’s fifty day moving average price is $2.15 and its two-hundred day moving average price is $2.36. Lisata Therapeutics has a 1 year low of $1.81 and a 1 year high of $4.17. The firm has a market capitalization of $36.25 million, a P/E ratio of -1.93 and a beta of 1.11.

Lisata Therapeutics (NASDAQ:LSTA) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.05. As a group, equities research analysts forecast that Lisata Therapeutics will post -2.66 EPS for the current fiscal year.

Hedge Funds Weigh In On Lisata Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in LSTA. Ground Swell Capital LLC bought a new position in Lisata Therapeutics in the third quarter valued at about $62,000. CIBC Bancorp USA Inc. bought a new position in Lisata Therapeutics in the 3rd quarter valued at approximately $37,000. Finally, Cerity Partners LLC acquired a new stake in Lisata Therapeutics during the 2nd quarter worth approximately $32,000. Institutional investors own 8.94% of the company’s stock.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches.

Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies.